



National Journal of Medical and Allied Sciences

[ISSN Online: 2319 – 6335, Print: 2393 – 9192|Original article |Open Access]

Website:-www.njmsonline.org

ROLE OF SERUM PROCALCITONIN IN EARLY DIAGNOSIS OF NEONATAL SEPSIS

Sandeep Kumar Sharma¹, Atosh Kumar², Berendra Yadav³, Ajay Kumar Singh⁴, Rakesh Pathak⁵, Muktiyaz Hussain⁶, Abhishek Sherma⁷

¹Assistant Professor, Department of Biochemistry, Major S.D.Singh Medical College Farrukhabad, U.P. India.

²Associate Professor, Department of Physiology, Major S.D.Singh Medical College Farrukhabad, U.P. India.

³Assistant Professor, ⁵Demonstrator, ⁷Lecturer, Department of Physiology, MRA Medical College, Ambedkarnagar, U.P. India. ⁴Assistant Professor, Department of Biochemistry, MRA Medical College, Ambedkarnagar, U.P. India. ⁶Lecturer, Department of Anatomy, MRA Medical College, Ambedkarnagar, U.P. India.

Abstract

Introduction: Neonatal sepsis is a major cause of neonatal mortality and morbidity throughout the world. The clinical findings of sepsis are uncertain in newborn infants and these findings may be associated with multiple conditions besides infection. The difficulty in making early diagnosis of neonatal sepsis, despite improved bacteriologic techniques, is attested to by recent reviews. Therefore a group of tests were studied to assess the usefulness of procalcitonin either singly or in combination in predicting neonatal sepsis. The aim of the present study is to evaluate the role of PCT as an early marker in diagnosis of neonatal sepsis.

Objective: The present study was undertaken to assess the role of serum procalcitonin in making early diagnosis of neonatal sepsis.

Methods: 100 cases of each confirmed neonatal sepsis and possible infection were included in the study and 100 age matched healthy neonates served as control. Serum Procalcitonin was determined by specific immunoluminometric assay (LUMItest®, Brahms Diagnostica GmbH, Berlin Germany).

Results: PCT differed significantly among infection categories ($p < 0.0001$) and correlated significantly with C-reactive protein at presentation (correlation coefficient 0.408, $p < 0.001$). PCT predicted 90.1% of definite infection. Receiver operating characteristic (ROC) analysis for PCT to predict definite infection showed odds ratio (OR) 1.168 (95% CI: 1.06-1.26). PCT had a negative predictive value of 0.98 (95% CI: 0.917-0.989) for definite infection.

Conclusion: Our findings suggest that PCT is of more value in ruling out neonatal sepsis on presentation in comparison to making the confirm diagnosis of neonatal sepsis, but it would be useful as part of a full sepsis evaluation.

Key words: PCT-Procalcitonin, CRP-C-reactive protein, ROC-Receiver operating characteristic, OR-Odds ratio, CI-Confidence interval

Author for correspondence: Dr. Atosh Kumar, Associate Professor, Department of Physiology, Major S.D.Singh Medical College, Farrukhabad, U.P. India. Tel: +91-7607098211 E-mail: dratosh@gmail.com

Introduction:

The importance of early treatment with antibiotics in newborns and infants with sepsis has been demonstrated by the sepsis home-treatment study performed by Bang and colleagues in rural India^{1,2}. But as the first sign of this disease is very nonspecific and there is no single reliable laboratory marker

available early rapid diagnosis is very problematic. Several leukocyte indices and acute-phase protein levels have been evaluated for the diagnosis of sepsis, and more recently, measurement of multiple plasma cytokines³ and leukocyte activation markers⁴ have showed promising results. However, to date, no single laboratory test has provided rapid and reliable

identification of early infected neonates. The best prediction is obtained using a combination of inflammatory markers including interleukin 6 (IL6) and interleukin 8 (IL8) and C-reactive protein (CRP). This inability has led to a search for new diagnostic markers^{5,6}. Serum procalcitonin (PCT) is one of many inflammatory markers and is now available as a routine laboratory investigation. PCT a prohormone of calcitonin occurs in very low concentration in the serum of normal individuals. PCT is preferentially induced in bacterial sepsis, especially in severe sepsis and septic shock^{7,8}. PCT can therefore be used to discriminate systemic inflammation due to bacterial sepsis from other causes and can also be used to monitor the progress and prognosis of patients with sepsis^{7,9}. The aim of the present study is to evaluate the role of PCT as an early marker in diagnosis of neonatal sepsis.

Material methods:

This prospective study was conducted on one hundred cases of neonatal sepsis conformed by positive blood culture, abnormal CRP, platelet count and WBC count and one hundred cases of possible infection having negative blood culture with abnormal CRP or a combination of at least two of the following abnormal platelet count, white cell count and CRP admitted in pediatrics department of Major S.D.Singh Medical College, Farrukhabad, India, from January 2012 to October 2013 were selected for the present study. Infants born to mothers with gestational diabetes were also excluded (because available data indicate that PCT values are higher for neonates born to diabetic mothers¹⁰). One hundred healthy neonates having negative blood culture, normal CRP, platelet count and white cell count were selected to serve as normal control. Blood samples were centrifuged within 30 minutes of collection. Serum was stored at -20° before analysis. All patients were entered in the study after written informed consent was obtained from the parent or guardian and the study was approved by the ethical committee of the Major S.D.Singh Medical College Farrukhabad.

Estimation of PCT

PCT was measured by a specific immunoluminometric assay (LUMItest®, Brahms Diagnostica GmbH, Berlin Germany), requiring

20µl of serum and 2hr to complete. The detection limit of this immunoluminometric assay is .08 ng/ml. Luminescence was measured automatically on a Lumat LB 9507 tube luminometer (Berthold Technologies GmbH & Co. KG, Bad Wildbad, Germany).

Statistical analysis

Continuous variable and proportions for categorical variables includes mean and standard deviation. Kruskal-Wallis one - way analysis of variance was done to determine whether any variable differed significantly among infection categories. Spearman's rank correlation and logistical regression were also done to determine the best predictors of infections. Receiver operating characteristics (ROC) analysis was done to evaluate the application of PCT as a diagnostic test for neonatal infection.

Results:

300 neonates were evaluated within the first 72 hours of life. The mean birth weight was 1985g (SD 897g) and gestational age 34.7 weeks (SD 4.3weeks). One-way analysis of variance (Kruskal-Wallis) showed that birth weight ($p=0.001$) gestational age ($p=0.0005$) and PCT ($p<0.0001$) differed significantly among healthy neonates and neonates with sepsis. Logistical regression and ROC analysis was performed among 'no infection' versus 'any infection' and 'no infection' versus 'definite infection'. PCT alone correctly predicted 73.65% of any infection and 90.1% of definite infection. If birth weight, gestational age and platelets were included, the prediction improved to 82.7% and 93.1% respectively. The predictive values for PCT using a cut off of 0.5ng/ml are shown in table 2. ROC analysis using PCT to predict 'no infection' versus 'any infection' gave an odds ratio (OR) of 1.136 (95% CIs 1.07- 1.26). The OR for the prediction of PCT for 'no infection' versus 'definite infection' was 1.168 (95% CI; 1.06- 1.26).

Table No. 1: Procalcitonin levels among the different categories

Category	Number of subjects	PCT level (median ng/dl)	Range	IQR
Healthy Neonate	100	0.47	32.6	0.67
Neonate with sepsis	100	8.21	35.8	12.85

Table No. 2: Predictive values for PCT < 0.5 NG/ML (95% CI)

category	Sensitivity	Specificity	Positive predictive value	Negative predictive value
None versus any infection	0.81 (0.724-0.847)	0.6 (0.431-0.573)	0.53 (0.402-0.541)	0.9 (0.748-0.868)
None versus definite infection	0.772 (0.708-0.784)	0.56 (0.416-0.587)	0.15 (0.087-0.217)	0.98 (0.917-0.989)

Discussion

Neonatal sepsis is a major cause of neonatal mortality and morbidity throughout the world. The clinical findings of sepsis are uncertain in newborn infants and these findings may be associated with multiple conditions besides infection. Acute phase reactants have been used frequently as an early marker of bacterial sepsis. Previous studies have shown CRP to be a useful marker of bacterial sepsis in the neonate. There is no single reliable test for the early confirmation of definite neonatal sepsis. Therefore, there is a continuing search for a new infection marker, including investigation of PCT.

In 1993, a study identified elevated level of PCT in patients with bacterial infection¹¹. Since then, PCT has become the most widely studied and reported putative biomarker for sepsis in children¹²⁻¹⁴. While circulating levels of PCT in healthy subjects are below the limit of detection, production of PCT during inflammation correlates with both the presence of bacterial endotoxin and inflammatory cytokines¹¹. PCT has been reported to:

- Differentiate between SIRS and sepsis¹⁵.
- Serve as a marker for sepsis in neonates^{16,17}.
- Identify children at high risk of death from sepsis after bone marrow transplant¹⁸.
- Have a better correlation with sepsis than CRP or WBC count in patients admitted to a pediatric intensive care unit¹⁹.
- Correlate with poor outcome in pediatric sepsis²⁰.
- Differentiate between fever of viral and bacterial etiology with more specificity than and similar sensitivity to CRP²¹.

However, other studies have reported that PCT is nonspecific and/or insensitive in the diagnosis of invasive fungal infections²², sepsis in burns patients²³, meningococemia²⁴, and neonatal sepsis²⁵.

PCT is a 116 amino acid peptide divided into 3 sections: amino terminus of PCT, immature calcitonin and calcitonin receptor-like receptor (CALC-1). It is encoded by CALC-1 gene located on chromosome¹¹.

It is expressed in tissue-specific manner (produced predominantly by monocytes and hepatocytes). PCT is synthesized to smaller peptides and mature calcitonin which is stored in secretory granules and secreted in the blood to regulate calcium concentration.

In the present study it is found that though PCT has a predictive role in neonatal sepsis but it is not sufficient alone as a sole marker of sepsis because specific cut-off values of PCT may be required in the first 48 hours of life, as various maternal and perinatal factors affect the PCT levels²⁶. The explanation for this difference in the PCT levels between two groups may be due to the fact that in absence of infection CALC-1 gene transcription in non-neuroendocrine tissue is suppressed except for thyroid gland C cells producing the precursor of calcitonin in healthy and non-infected individuals. In presence of infection, non-neuroendocrine tissue (parenchymal tissue and differentiated cell types) express the CALC-1 gene to produce increased levels of PCT; function of this increase is currently unknown.

The negative predictive value for definite infection in our study is 98%. This is in agreement with Guibourdenche et al²⁷ who have suggested that a

negative PCT on presentation may be useful to rule out sepsis in neonates.

Conclusion:

From above study we reach to the conclusion that PCT alone is of moderate diagnostic value for the detection of neonatal sepsis. PCT alone is insufficient in confirming the diagnosis of neonatal sepsis, but would be useful as part of a sepsis evaluation. A negative PCT at presentation may be useful to rule out sepsis, but this should be evaluated further.

References:

1. Bang AT, Bang RA, Reddy MH. Simple clinical criteria to identify sepsis or pneumonia in neonates in the community needing treatment or referral. *Pediatr Infect Dis J.* 2005;**24**:335–41.
2. Bang AT, Bang RA, Baitule SB . Effect of home-based neonatal care and management of sepsis on neonatal mortality: field trial in rural India. *Lancet.* 1999;**354**:1955–61.
3. Hodge G, Hodge S, Haslam R, McPhee A, Sepulveda H, Morgan E, et al. Rapid simultaneous measurement of multiple cytokines using 100 microl sample volumes--association with neonatal sepsis. *Clin Exp Immunol.* 2004;**137**:402–407.
4. Hodge G, Hodge S, Han P, Haslam R. Multiple leucocyte activation markers to detect neonatal infection. *Clin Exp Immunol.* 2004;**135**:125–129.
5. Polin RA. The "ins and outs" of neonatal sepsis. *J Pediatr.* 2003;**143**:3–4.
6. Weinberg GA, Powell KR. Laboratory aids for diagnosis of neonatal sepsis. In: Remington JS and Klein JO, editor. *Infectious diseases of the fetus and newborn infant.* Philadelphia, Saunders. 2001; 1327–1344.
7. Meisner M. Pathobiochemistry and clinical use of procalcitonin. *Clin Chim Acta.* 2002; **323**: 17–29.
8. Giamarellos- Bourboulis EJ, Mega A, Grecka P. Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient? *Intensive Care Med.* 2002; **28**: 1351–1356.
9. Athan F, Akagunduz B, Genel F, Bak M, Can D. Procalcitonin: a marker of neonatal sepsis. *Trop Pediatr.* 2002; **48**: 10–14.
10. Chiesa C, Panero A, Rossi N, Stegagno M, De Giusti M, Osborn JF, et al. Reliability of procalcitonin concentrations for the diagnosis of sepsis in critically ill neonates. *Clin Infect Dis.* 1998;**26**:664–672.
11. Maruna P, Nedelnikova K, Gurlich R. Physiology and genetics of procalcitonin. *Physiol Res.* 2000;**49**:S57–61.
12. Leclerc F, Cremer R, Noizet O. Procalcitonin as a diagnostic and prognostic biomarker of sepsis in critically ill children. *Pediatr Crit Care Med.* 2003;**4**:264–6.
13. Mariscalco MM. Is plasma procalcitonin ready for prime time in the pediatric intensive care unit? *Pediatr Crit Care Med.* 2003;**4**:118–9.
14. Meisner M. Biomarkers of sepsis: clinically useful? *Curr Opin Crit Care.* 2005;**11**:473–80.
15. Arkader R, Troster EJ, Lopes MR . Procalcitonin does discriminate between sepsis and systemic inflammatory response syndrome. *Arch Dis Child.* 2006;**91**:117–20.
16. Athan F, Akagunduz B, Genel F . Procalcitonin: a marker of neonatal sepsis. *J Trop Pediatr.* 2002;**48**:10–4.
17. Pavcnik-Arnol M, Hojker S, Derganc M. Lipopolysaccharide-binding protein in critically ill neonates and children with suspected infection: comparison with procalcitonin, interleukin-6, and C-reactive protein. *Intensive Care Med.* 2004;**30**:1454–60.
18. Sauer M, Tiede K, Fuchs D . Procalcitonin, C-reactive protein, and endotoxin after bone marrow transplantation: identification of children at high risk of morbidity and mortality from sepsis. *Bone Marrow Transplant.* 2003;**31**:1137–42.
19. Casado-Flores J, Blanco-Quiros A, Asensio J . Serum procalcitonin in children with suspected sepsis: a comparison with C-reactive protein and neutrophil count. *Pediatr Crit Care Med.* 2003;**4**:190–5.

20. Han YY, Doughty LA, Kofos D . Procalcitonin is persistently increased among children with poor outcome from bacterial sepsis. *Pediatr Crit Care Med.*2003;**4**:21–5.
21. Fernandez Lopez A, LuacesCubells C, Garcia Garcia JJ . Procalcitonin in pediatric emergency departments for the early diagnosis of invasive bacterial infections in febrile infants: results of a multicenter study and utility of a rapid qualitative test for this marker. *Pediatr Infect Dis J.*2003;**22**:895–903.
22. Dornbusch HJ, Strenger V, Kerbl R . Procalcitonin – a marker of invasive fungal infection? *Support Care Cancer.*2005;**13**:343–6.
23. Neely AN, Fowler LA, Kagan RJ . Procalcitonin in pediatric burn patients: an early indicator of sepsis? *J Burn Care Rehabil.* 2004;**25**:76–80.
24. Van der Kaay DC, De Kleijn ED, De Rijke YB . Procalcitonin as a prognostic marker in meningococcal disease. *Intensive Care Med.*2002;**28**:1606–12.
25. Bonac B, Derganc M, Wraber B . Interleukin-8 and procalcitonin in early diagnosis of early severe bacterial infection in critically ill neonates. *Pflugers Arch.* 2000;**440**(5):72–4.
26. Chiesa C, Pellegrini G, Panero A . C-reactive protein, interleukin 6 and procalcitonin in the immediate post natal period: influence of illness severity, risk status, antenatal and perinatal complications and infection. *Clin Chem.* 2003;**49**:60-68.
27. Guibourdenche J, Bedu A. Biochemical markers of neonatal sepsis; value of procalcitonin in the emergency setting. *Ann Clin Biochem.* 2002; **39**:130-135

Conflicts of Interest: None Funding: None

Citation: Sharma SK, Kumar A, Yadav B, Singh AK, Pathak R, Hussain M, Sherma A. Role of Serum Procalcitonin in Early Diagnosis of Neonatal Sepsis. National Journal of Medical and Allied Sciences 2015; 4(1):62-66